Pluristem Therapeutics to Expand Manufacturing With New GMP Facility Capable of an Annual Production Capacity of Over $1 Billion

HAIFA, Israel, July 26, 2011 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), announced today that its wholly owned Israeli subsidiary, Pluristem Ltd., has entered into an agreement with MTM – Scientific Industries Center Haifa Ltd., for the leasing and construction of a new state-of-the-art GMP manufacturing facility. The new facility will be located near the company's headquarters and existing facilities in MATAM Park, Haifa, Israel and will support the manufacturing of Pluristem's PLX (PLacental eXpanded) cell product candidates for the treatment of critical limb ischemia (CLI), intermittent claudication (IC), adjuvant hip replacement surgery, muscle injuries, pulmonary hypertension (PH) and other diseases. According to the agreement, the lease of the new facility will commence as of January 2012 for a period of approximately 5 years with an option to extend the lease for an additional 5 years.

Back to news